Literature DB >> 15916292

Glucose-6-phosphate dehydrogenase deficiency in two returning Operation Iraqi Freedom soldiers who developed hemolytic anemia while receiving primaquine prophylaxis for malaria.

Marcus E Carr1, Matthew N Fandre, Felix O Oduwa.   

Abstract

Use of antimalarial prophylaxis continues to be routine practice among military personnel returning from areas where malaria is endemic. Primaquine may be used for terminal prophylaxis against Plasmodium ovale and Plasmodium vivax. Serious complications of this regimen are infrequent. We report the occurrence of significant hemolytic anemia for two soldiers returning from Operation Iraqi Freedom. They presented with dark urine, headaches, and classic laboratory findings of hemolysis. Both soldiers were subsequently found to have glucose-6-phosphate dehydrogenase deficiency, and both responded to conservative treatment and cessation of medication. Although this complication is unusual, medical personnel involved in the care of recently returned deployed service members should be alert to its potential occurrence among patients who are receiving antimalarial prophylaxis. This complication could be completely avoided with prescreening of personnel for glucose-6-phosphate dehydrogenase deficiency, as is currently done in the Air Force and Navy, before the use of primaquine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15916292     DOI: 10.7205/milmed.170.4.273

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Improved quantitative method for G6PD deficiency detection.

Authors:  Yun-Hua Fan; LuAnn Lazenbery; Elizabeth Foster; Felix Duelm; Earl Grant
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

2.  Evaluation of a rapid qualitative enzyme chromatographic test for glucose-6-phosphate dehydrogenase deficiency.

Authors:  Kathleen E Tinley; Anita M Loughlin; Anne Jepson; Elizabeth D Barnett
Journal:  Am J Trop Med Hyg       Date:  2010-02       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.